MDxHealth SA (OTC:MXDHF) Q3 2023 Earnings Convention Name November 8, 2023 4:30 PM ET
Firm Members
Michael McGarrity – Chief Government Officer
Ron Kalfus – Chief Monetary Officer
Convention Name Members
Daniel Sammarco – TD Cowen
Andrew Brackmann – William Blair
Thomas Vranken – KBC Securities
Operator
Good afternoon, women and gents, and welcome to the MDxHealth Third Quarter 2023 Earnings Name. Earlier than we start, I want to remind everybody that we’ll make forward-looking statements throughout immediately’s name, whether or not in ready remarks or through the Q&A session. These forward-looking statements are topic to inherent dangers and uncertainties. These dangers and uncertainties are detailed within the Threat Components part of our filings with the Securities and Change Fee, particularly within the firm’s annual report on Type 20-F.
Right now, all traces are in a listen-only mode. Following the presentation, we’ll conduct a query and reply session. [Operator Instructions] Additionally be aware that this name is being recorded on Wednesday, November 8, 2023.
And I want to flip the convention over to Michael McGarrity, Chief Government Officer. Please go forward, sir.
Michael McGarrity
Thanks Sylvie, and thanks all for becoming a member of us for our third quarter 2023 earnings name for MDxHealth. With me immediately is Ron Kalfus, Chief Monetary Officer. In the present day’s feedback might be temporary and function a complement to our Q3 pre-release.
Third quarter outcomes show our continued execution and dedication to ship sturdy and sustainable development for all of our stakeholders by specializing in business execution and working self-discipline.
Primarily based upon the numerous enhancements made throughout our enterprise, together with our industry-leading diagnostic product menu, targeted business group and general working effectivity, we imagine MDxHealth is now on a path to ship sturdy and sustainable development that can result in working profitability within the first half of 2025.
Because the third quarter outcomes show, this execution is translating into enhancements throughout our whole P&L. Income has elevated from $11 million in 2019 to the high-end of our $65 million to $70 million steering for this yr, 2023. And income for the primary 9 months of 2023 has greater than doubled versus the prior yr interval.
Gross margin has expanded greater than 20 proportion factors from midyear final yr to 65%. Working bills have been managed and truly declined in Q3 year-over-year. Working loss has been greater than reduce in half, with a 62% discount for Q3 year-over-year. And money burn has declined by nearly 50% from This autumn, 2022. These throughout the board enhancements to our P&L give us visibility to working profitability within the first half of 2025 and show why MDxHealth is a novel outlier in comparison with many different small-cap development corporations within the life sciences diagnostics sector. Over time, we count on traders will recognize this distinction and more and more view MDxHealth as a premier excessive development chief in precision diagnostics with working profitability focused within the coming quarters, not years.
Additional constructing upon this expectation, we’re more than happy to have garnered just about unanimous shareholder assist for our delisting from Euronext and consolidation of our buying and selling to NASDAQ as permitted on November 3. We count on the consolidating and the buying and selling of our frequent inventory onto a single change will enhance buying and selling liquidity and scale back our administrative prices going ahead.
Earlier than discussing our quarterly leads to extra element, I feel you will need to step again and touch upon the final 4 years of our transformation of MDxHealth. First, we made vital adjustments in our management and gross sales workforce to make sure business execution and working self-discipline. As I’ve commented, we now have 70 individuals in our subject gross sales group, with solely 5 of them remaining from 2019, reflecting the total scale restructuring of that workforce, as we prioritize expertise, focus, incentive compensation and efficiency expectations.
Second, we navigated via the pandemic with out compromising on this progress. Regardless of incurring further working bills over this difficult interval, it’s now clear that our workforce’s progress in advancing our initiatives lay the inspiration for the bettering development and monetary metrics that we have now skilled over the past variety of quarters. We additionally resisted the ballot of the pivot to COVID testing, which whereas tempting, we felt could be dilutive to our strategic focus.
Third, we executed a transformational acquisition of the GPS Check, which has solidified our complete menu and established MDxHealth, as the one supplier of a clinically actionable check at every level within the diagnostic pathway of prostate most cancers. Importantly, GPS, together with our choose and confirmed checks, are all coated by Medicare and included within the NCCN tips.
And eventually, we validated the power of our restructured gross sales workforce by introducing our first channel alternative with the launch in 2022 of our Resolve mdx check. Resolve mdx is marketed to our urology specialist buyer base the place advanced and sometimes multi-organism urinary tract infections with particular susceptibility profiles, which within the first few quarters of gross sales is on a $10 million annualized run fee.
I’ll present an extra view ahead, however first, let me flip the decision over to Ron for a overview of our monetary and working outcomes for Q3. Ron?
Ron Kalfus
Thanks, Mike. As Mike talked about, we’re happy to report our optimistic outcomes for the third quarter of 2023. Revenues from the third quarter ended September 30, 2023 elevated by 73% to $19.3 million versus $11.2 million for the third quarter of 2022. Excluding GPS, third quarter income elevated by 45% versus final yr.
Third quarter revenues of $19.3 million have been comprised of $8.1 million from GPS, $6.6 million from Affirm, $2.7 million from Resolve, and $1.9 million from Choose. For the 9 months ended September 30, 2023, our revenues have been $50.8 million, representing a rise of 110% over the identical interval final yr. Excluding GPS, 9 months income elevated 38% over the identical interval final yr.
Transferring under the income line, our gross revenue for the third quarter was $12.6 million, a rise of 102% as in comparison with $6.2 million for the third quarter of 2022. Gross margins have been 64.9% for Q3, 2023 as in comparison with 55.8% for Q3, 2022, an enchancment of 908 foundation factors.
For the three months ended — excuse me — for the 9 months ended September 30, 2023, gross revenue was $31.3 million, a rise of 161% as in comparison with $12 million for the primary 9 months of 2022. Gross margins have been 61.5% for the primary 9 months of 2023 as in comparison with 49.6% for the primary 9 months of 2022, an enchancment of 1,190 foundation factors.
Working loss for the third quarter was $4.6 million in comparison with $11.9 million for the third quarter of 2022, representing a discount of 62% pushed by improved margin and a 6% discount in working bills. For the nine-month interval, working loss was $21 million in comparison with $29 million for a similar interval final yr, a discount of 27%, pushed by improved margins, partially offset by a rise in working bills associated to the extra subject gross sales personnel related to the GPS acquisition.
Money and money equivalents as of September 30, 2023, have been $32.7 million. Our complete use of money for the third quarter was $6.8 million, down 23% sequentially from $8.8 million within the second quarter.
This concludes my temporary overview of the outcomes, and I’ll now flip the decision again to Mike.
Michael McGarrity
Thanks Ron. Since becoming a member of MDxHealth as CEO 4 years in the past, I’ve constantly maintained that our main strategic goal is to create a world-class precision diagnostics firm able to delivering sturdy, sustainable development with a transparent path to profitability. I can say with out reservation that we’re delivering on that dedication.
Our menu and income development alternatives look very totally different immediately than they did in 2019 and even initially of 2022. Leveraging the power of our gross sales channel, we stay targeted on figuring out new alternatives that can proceed to drive development. Briefly, whereas our menu appears to be like fairly totally different immediately than it did simply 18 months in the past, we might count on it should look totally different 18 months from now.
When contemplating any further development alternatives, we’ll all the time apply the identical self-discipline as we did with Resolve mdx, which includes conducting a rigorous due diligence course of, analyzing market entry, confirming complementary focus to our present menu and assessing the accretive influence to our gross margin and P&L dynamics.
As we efficiently execute on our enterprise growth technique, we additionally count on to draw a rising variety of potential traders and companions, who will more and more acknowledge MDxHealth’s management place in urological life science diagnostics, and the numerous development alternatives that lie forward for the corporate.
So, as we glance ahead, MDxHealth is dedicated to driving sustainable development, which is able to function the inspiration for worth creation for all of our stakeholders, together with sufferers, prospects, and shareholders.
Thanks to your curiosity in and assist of MDxHealth, and now I will flip the decision again over to Sylvie for questions.
Query-and-Reply Session
Operator
Thanks, sir. [Operator Instructions]
And your first query might be from Dan Brennan at TD Cowen. Please go forward.
Daniel Sammarco
Hello, Michael and Ron. Good night. Thanks for taking questions tonight. That is Dan Sammarco on for Dan Brennan. Would you thoughts offering us with any element on ideas about business protection time traces for Choose?
Michael McGarrity
Yeah. Dan, so, we clearly communicated protection of our Choose check by Medicare in Q2 of final yr of 2020 — I am sorry — of 2022. And as I’ve famous, that’s often historically the catalyst for broader business protection. And subsequent to that, we additionally introduced protection for our Choose check by Cigna. And we do not put out a launch or talk publicly each contract that we choose up, however that was clearly a significant and materials accomplishment following our Medicare protection. And our market entry managed care workforce actually have two drivers of development for our prime line of the enterprise.
The primary is our gross sales workforce, which drives adoption of models into our buyer base, after which our market entry managed care workforce, which is a part of our business workforce as properly, it drives protection, which exhibits up in our ASP, most notably is the place that would seem. So, we have seen progress in each fronts and we count on that to proceed.
Daniel Sammarco
All proper. Nice. Thanks. After which when it comes to coming in on the prime finish of your information for 2023, might you give us any preliminary ideas on what you are seeing for 2024? And possibly contact a bit bit extra on the precise components driving power in Resolve.
Michael McGarrity
Yeah. So, I will begin with the second half. I imply, as I’ve famous, I feel what we’re seeing is candidly what we anticipated, and that was based mostly on the work we did prior and the validation of all of the elements from a possibility match, entry and viability of that we’re offering an actual resolution. It is actually necessary to notice that our checks that we provide to our urology buyer base is a extremely advanced check of each organisms and particular susceptibility profiles for these organisms. So, the affected person inhabitants that presents to urology may be very totally different than Medicare setting or another settings the place UTI presents. These are sufferers which have comorbidities, whether or not or not it’s enlarged prostate or BPH, which might result in not solely advanced multi-organism infections, however serial infections and therefore, the referral to a urologist. So, we’re assured that every part we labored to find and validate the diligence course of is coming via as anticipated.
So far as 2024, at this level, we’ll report — we’ll probably count on to and plan to report a pre-release of our income and money and sure a primary visibility to 2024 initially of January along with the J.P. Morgan convention.
Daniel Sammarco
All proper. Nice. Respect the decision. You guys have a very good evening.
Operator
Thanks. Subsequent query might be from Andrew Brackmann at William Blair. Please go forward.
Andrew Brackmann
Hey, guys. Good afternoon. Thanks for taking the query. Are you able to possibly give a bit bit extra coloration across the latest wins from the cross-selling initiatives between Affirm and GPS? Simply attempting to kind of higher perceive how we must always take into consideration the sturdiness of development in each these franchises now that they are in the identical bag. Thanks.
Michael McGarrity
Yeah. Andrew, we really feel assured that we’re seeing what we anticipated the complexity of the mixing I’ve spoken to. So, we really feel like the primary couple of quarters of this yr, we have been nonetheless within the strategy of resetting and restructuring each gross sales territory as we introduced over — it went from 30 reps to simply over 50 reps [indiscernible], as a former gross sales rep, a major quantity of disruption in every territory and a few changeover on buyer relationships, we really feel actually optimistic about the way in which we navigate and execute via that, patiently ensuring that our gross sales workforce was held collectively and that our — all of our change in our packages and incentive comp supplied a very good basis for execution and development. I feel as we regarded over the past couple of quarters, that is starting to point out up in our — notably with Affirm, Choose put up preliminary biopsy.
My remark about being the one firm that may present a medical actionable diagnostic outcome at every level within the pathway. We expect that is crucial and we count on execution and development to proceed for each of these. As we go ahead, we’ll present visibility to some metrics that we observe right here internally that we measure to and handle that progress.
Andrew Brackmann
Okay. That is good. After which, I simply wish to kind of follow-up on a few of your feedback about adjustments within the group traditionally and the way you kind of see it evolving over time. Are you able to possibly simply speak a bit bit extra about what classes inside urology might sound to suit higher than others as you kind of take into consideration including to the bag right here over the following handful of quarters and years? Thanks.
Michael McGarrity
Certain, Andrew. I feel you have made a few factors which are necessary to notice. So, our objective, and it was with Resolve was no exception and going ahead, might be no exception is that we’re not simply seeking to put extra worth into our gross sales reps’ luggage, however not our focus or the idea for the initiative.
We solely wish to do sensible issues that we expect Resolve mdx was actually necessary to validate that, proper? And we will not actually screw that one up. It would not converse to what we expect we have now within the subject. So, really, we expect that the identical diligence course of applies to any development alternative, whether or not or not it’s via the license or partnership or distribution or acquisition that can observe that very same self-discipline so far as do we have now entry? Is it complementary to and never dilutive of our present focus inside prostate most cancers and urology extra broadly? And does it present — is it accretive to our P&L from a gross margin perspective? And may we proceed to drive execution development in addition to the 2 levers that I pointed to beforehand from a gross sales workforce driving models and market entry driving protection? So, we’re assured to that.
And I’ve mentioned we needed to do two issues with our enterprise. Over the past 4 years, we have now derisked the enterprise, which we expect we’re demonstrating with our clear path to excessive income, best-in-class gross margin trajectory and profitability. So, we’re assured that we’re turning into extra apparent in that regard. So, the place we have been all the time targeted on development, searching on it, I feel we’re — it will be truthful to say there’s extra inbound coming, however we’ll solely be very prudent and sensible about what we might elect to do with our — what I feel is our most respected asset, which is our gross sales workforce and channel.
Andrew Brackmann
Okay. Thanks guys.
Michael McGarrity
Thanks Andrew.
Operator
Subsequent query might be from Thomas Vranken at KBC Securities. Please go forward.
Thomas Vranken
Hello, and thanks for taking my questions. And by the way in which, congratulations on the very stable P&L enchancment. I needed to zoom in a bit bit extra about — on these gross margins they usually have advanced very favorably this quarter. Simply needed to have a bit — choose your brains a bit and the way you see that evolving into 2024? To which extent ought to we anticipate an influence of these growing Choose volumes?
Michael McGarrity
Certain, Thomas. Thanks for collaborating. We anticipated this trajectory and it is really coming proper on or really forward of the place we anticipated. So, should you look again, as I famous to the midyear of final yr, we have been operating low 40% gross margins and that was a perform of — we actually solely have one product producing income with Affirm. We have subsequently added the GPS check, which carries broad protection, our Resolve mdx check and protection coming over Choose in Q2. So, we actually really feel like every of these, as we anticipated, is accretive to our gross margin, which clearly, as I’ve famous, was a key part to the rationale for the GPS acquisition and every of the selections we have made about our product providing.
So, what we’re delivering right here on the gross margin is what we anticipated. So far as development from right here, do I imagine that in the end our gross margin can begin with the 7%? That is an inexpensive assumption, and we’ll proceed to construct out protection, and as I famous, potential further growth of our menu.
Thomas Vranken
All proper. Thanks. And likewise I needed to zoom in on the GPS check a bit. Primarily based on the place you stand immediately, how ought to we take into consideration these contingent issues within the coming quarters and years? Do you count on all of these earn-out funds to be triggers at this level?
Michael McGarrity
Yeah. Thomas, in order you are conscious, we really feel just like the modification we made with Precise Sciences on the earnout was crucial, optimistic and favorable, the place we — the earnout interval went from 2023, 2024 and 2025 to — I am sorry — from 2024, 2025 and 2026 to 2025, 2026 and 2027. And I’ve mentioned from the start the day of the acquisition that we totally count on to pay the total earnout, as a result of it is based mostly on income and development of the GPS product providing. And our enterprise is modeled to reaching these milestones as it will mirror positively on our prime line, our P&L and our profitability.
So, sure is my reply. We count on to make these funds. What we really feel optimistic about is the timing and the partnership with Precise Science, which Precise Sciences — which clearly confirmed confidence in our potential to execute and to ship.
Thomas Vranken
Okay. Thanks.
Michael McGarrity
Thanks Thomas.
Operator
And presently, Mr. McGarrity, we have now no different questions registered. Please proceed with further feedback.
Finish of Q&A
Michael McGarrity
I haven’t got any further feedback, Sylvie, aside from to thank all people for his or her participation and assist. We look ahead to reporting the following time. And in meantime, we’ll return to give attention to execution. Thanks all.
Operator
Thanks, sir. Women and gents, this does certainly conclude your convention name for immediately. As soon as once more, thanks for attending, and presently we do ask that you just please disconnect your traces.
